Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It operates in more than 35 countries worldwide.
é«ãå©çæé·
å瀟ã®çŽå©çã¯æ¥çããªãŒãããŠãããææ°ã®å¹ŽéçŽå©çã¯USD 29.44Bã§ãã
é«é
åœ
å瀟ã¯é«é
åœéæã§ãããææ°ã®é
åœæ§åã¯814.79%ã§ãã
å®å®é
åœ
å瀟ã¯éå»5幎éã«ãããç¶ç¶çã«é
åœã宿œããŠãããææ°ã®é
åœæ§åã¯814.79%ã§ãã
å²å®
åç€Ÿã®ææ°ã®PEã¯16.88ã§ãéå»3幎éã®æ°Žæºãšæ¯èŒããŠå®å€åã«ãããŸãã
æ©é¢æè³å®¶ã®å£²ãè¶ã
ææ°ã®æ©é¢æè³å®¶ã®ä¿ææ ªæ°ã¯1.14Bæ ªã§ãåååææ¯ã§0.22%æžå°ããŠããŸãã
ãžã§ãŒã ãºã»ã·ã¢ã³ãºãä¿æ
ã¹ã¿ãŒæè³å®¶ãžã§ãŒã ãºã»ã·ã¢ã³ãºã¯æ¬éæã0.00æ ªä¿æããŠããŸãã
åžå ޿޻åãæŽ»çº
å瀟ãžã®æè³å®¶ã®é¢å¿ãé«ãŸã£ãŠããã20æ¥éã®å£²è²·å転çã¯0.22ã§ãã